OBJECTIVE The effects of preventive interventions on cardiovascular autonomic neuropathy
(CAN) remain unclear. We examined the effect of intensively treating traditional risk factors …

OBJECTIVE To examine whether cardiovascular autonomic neuropathy (CAN) is an
independent risk factor of cardiovascular disease (CVD) events during DCCT/EDIC …

OBJECTIVE Intensive therapy targeting normal blood glucose increased mortality compared
with standard treatment in a randomized clinical trial of 10,251 participants with type 2 …

Cardiovascular autonomic neuropathy (CAN) is a risk factor for cardiovascular disease
(CVD) and mortality in patients with type 2 diabetes. This study evaluated the relationship …

OBJECTIVE To examine the course of cardiovascular autonomic neuropathy (CAN) and
related cardiometabolic risk factors in patients with type 2 diabetes. RESEARCH DESIGN …

Background To examine whether the progression rate of cardiovascular autonomic
neuropathy (CAN) stage is an independent predictive factor for cardiovascular disease …

Cardiovascular disease (CVD) is a ma-jor cause of death in patients with type 2 diabetes.
Unclear, however, is the effect of intensive therapy in reducing the development of …

Cardiovascular autonomic neuropathy (CAN) in diabetes is generally overlooked in practice,
although awareness of its serious consequences is emerging. Challenges in understanding …

The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and
Complications (DCCT/EDIC) study demonstrated that intensive glucose control reduced the …

Aims/hypothesis Cardiac autonomic neuropathy (CAN) is associated with increased
morbidity and mortality in type 1 diabetes. Apart from glycaemic control, risk factors for CAN …